www.ebmt.org

EBMT Activity Survey 2017683 Teams

41,100 Patients45,418 Transplants

49 CountriesFor internal use only.

For any other use, please contact Helen Baldomero for permission: helen.baldomero@usb.ch

Provided by the EBMT Activity Survey Office: not for publication

March 2019

EBMT Activity Survey in 2017: Patient and transplant numbers

Allogeneic

HSCT

Autologous

HSCT Total

1st allo/1st auto HSCT

Additional HSCT

TOTAL

Teams: 683 (of 710) Countries reporting: 49

17,155

1,126

18,281

23,945

3,192

27,137

41,100

4,318

45,418

Indication

March 2019

EBMT Activity Survey in 2017: Donor type and stem cell source: all transplants

BM PBSC

HLA-id sibling

Haplo-identical

Other family

Syngeneic

Unrelated

Allogeneic

Autologous

1,420

708

89

n.a.

1,492

3,709

112

5,864

2,689

306

21

9,401

18,281

27,137

Total

4,411

1,981

212

n.a.

7,579

14,204

27,022

Donor type

Stem Cell Source

Cord

33

n.a.

5

n.a.

330

368

3

March 2019

EBMT Activity Survey 2017:Main indications

Allogeneic

1st HSCT

Autologous

1st HSCT Total

Myeloid (AML, CML, MDS/MPN)

Lymphoid (ALL, CLL, HL, NHL)

Plasma cell disorder

Solid tumor

Non-malignant disorders

bone marrow failure

Other

Total Patients

9,772

4,630

385

36

2,173

802

159

17,155

375

8,781

12,692

1,571

494

1

32

23,945

10,147

13,411

13,077

1,607

2,667

803

191

41,100

Indication

March 2019

Allogeneic HSCT in Europe 20171st HSCT

AML, 39%

CML, 2%

MDS, 12%MPN, 4%

ALL, 16%

CLL, 1%

PCD, 2%

HL, 3%

NHL, 7.5%

Solid tumors, 0.2%

BMF, 5%

HG, 4%

PID, 3%IDM, 0.9%

AID, 0.1%

Others, 1%

Provided by the EBMT Activity Survey Office: not for publication

March 2019

Autologous HSCT in Europe 20171st HSCT

Myeloid disorders, 2%

ALL/CLL, 0.4%

PCD, 53%

HL, 9%

NHL, 27%

Neuroblastoma, 2%

Soft tissue/Ewing, 1%

Germinal tumors , 2%

Breast, 0.1%

Other ST, 2% NMD, 0.1%

AID, 2%

Others , 0.1%

Provided by the EBMT Activity Survey Office: not for publication

March 2019

HSCT Activity in Europe 1990-2017:Transplant type 1st HSCT

Provided by the EBMT Activity Survey Office: not for publication

March 2019

HSCT Activity in Europe 1990-2017:Main indications: allogeneic 1st. HSCT

Provided by the EBMT Activity Survey Office: not for publication

March 2019

HSCT Activity in Europe 1990-2017:Main indications: autologous 1st. HSCT

Provided by the EBMT Activity Survey Office: not for publication

March 2019

HSCT Activity in Europe 1990-2017:donor origin: 1st. HSCT

Provided by the EBMT Activity Survey Office: not for publication

March 2019

HSCT - rates in Europe 2017

N. allogeneic transplants

per 10 million population

0 or no report

0.1 - 100

101 - 150

151 – 200

201 – 300

> 300

Algeria, Iran, Iraq, Lebanon, Nigeria, South Africa, Tunisia

Jordan, Saudi Arabia

Israel

Provided by the EBMT Activity Survey Office: not for publication

March 2019

HSCT - rates in Europe 2017

N. autologous transplants

per 10 million population

0 or no report

1 - 100

101 - 300

301 – 400

401 – 500

> 500

Algeria, Iran, Iraq, Jordan, Lebanon, Saudi Arabia, South Africa,

Tunisia

Israel

Provided by the EBMT Activity Survey Office: not for publication